Basic Information
FLUTIFORM® PRESSURISED INHALATION, SUSPENSION 250 MICROGRAM/10 MICROGRAM PER ACTUATION
AEROSOL, METERED
Regulatory Information
SIN14551P
May 19, 2014
Prescription Only
Therapeutic
RESPIRATORY (INHALATION)
August 10, 2023
May 30, 2025
XR03AK07
Company Information
Active Ingredients
Strength: 250 mcg/actuation
Strength: 10 mcg/actuation
Detailed Information
Contraindications
**4.3 Contraindications** Hypersensitivity to any of the active substances or to any of the excipients (see section 6.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).
Indication Information
**4.1 Therapeutic indications** This fixed-dose combination of fluticasone propionate and formoterol fumarate ( _**Flutiform**_ ® inhaler) is indicated in the regular treatment of asthma where the use of a combination product (an inhaled corticosteroid and a long-acting β2 agonist) is appropriate: - For patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short-acting β2 agonist. Or - For patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist. _**Flutiform**_ ® 50 microgram/5 microgram is indicated in adults, adolescents and children aged 5 years and above. _**Flutiform**_ ® 125 microgram/5 microgram is indicated in adults and adolescents aged 12 years and above. _**Flutiform**_ ® 250 microgram/10 microgram inhaler is indicated in adults only.